Kowa Pharmaceuticals America, Inc. Enters into Co-Promotion Agreement with Allergan for BYSTOLIC® (nebivolol) in the United States - Argus Press

Kowa Pharmaceuticals America, Inc. Enters into Co-Promotion Agreement with Allergan for BYSTOLIC® (nebivolol) in the United States  Argus Press

MONTGOMERY, Ala.--(BUSINESS WIRE)--Jan 28, 2019--Kowa Pharmaceuticals America, Inc. announced today that it has entered into an agreement with ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more